PTHS
$23.2
$
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.
Next Earnings
2026-02-25
Beta
4.077
Average Volume
Market Cap
Last Dividend
CIK
0001919246
ISIN
US1711262048
CUSIP
CEO
Scott Plesha
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
4
IPO Date
2025-07-02
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics | FARMINGTON, Conn.--(BUSINESS WIRE)--Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”) (the “Company”), an affiliate of Monroe Capital, today announced it has provided a $50 million venture loan facility to Pelthos Therapeutics Inc. (NYSE American: PTHS) (“Pelthos”), with an initial funding of $30 million, and up to $20 million to support future growth. Pelthos is a publicly traded biopharmaceutical company that is licensed to commercialize ZELSUVMI™ (berdazimer) topical gel, an. | Business Wire | 2026-01-15 16:10:00 |
| Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance | The minimally dilutive funding will accelerate Pelthos' highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum, two newly acquired FDA approved cutaneous infectious disease products and for working capital and general corporate purposes The minimally dilutive funding will accelerate Pelthos' highly successful commercialization efforts for its lead product, ZELSUVMI™ (berdazimer) topical gel, 10.3% for the treatment of molluscum contagiosum, two newly acquired FDA approved cutaneous infectious disease products and for working capital and general corporate purposes | GlobeNewsWire | 2026-01-13 08:30:00 |
| Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice | DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has acquired Xeglyze® (abametapir) from Hatchtech Pty Ltd., an Australian biotech company, for $1.8 million. | GlobeNewsWire | 2026-01-05 07:30:00 |
| Pelthos Pharmaceuticals: Off To A Strong Start With Zelsuvmi, Continued Sales Growth Is Likely | Pelthos Pharmaceuticals has launched Zelsuvmi, the first at-home FDA-approved treatment for molluscum contagiosum, showing strong initial sales growth. PTHS reported $7.1 million net revenue in its first commercialization quarter, prompting an expansion of its sales force. The company targets breakeven by end-2026, with peak revenue projections of $175 million likely conservative given rapid prescription uptake and market size. | Seeking Alpha | 2025-12-01 18:34:51 |
Algorithm Performance
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|